PMID- 33471673
OWN - NLM
STAT- MEDLINE
DCOM- 20210122
LR  - 20210122
IS  - 1530-891X (Print)
IS  - 1530-891X (Linking)
VI  - 26
IP  - 8
DP  - 2020 Aug
TI  - Similar Cardiovascular Outcomes Between Insulin Detemir and Insulin Glargine In 
      Type 2 Diabetic Patients With Extremely Atherosclerotic Cardiovascular Disease 
      Risks.
PG  - 818-829
LID - S1530-891X(20)48165-0 [pii]
LID - 10.4158/EP-2019-0552 [doi]
AB  - OBJECTIVE: The cardiovascular outcomes of insulin detemir in patients with type 2 
      diabetes mellitus (T2DM) after acute coronary syndrome (ACS) or acute ischemic 
      stroke (AIS) are unclear. The aim of our real-life cohort study was to evaluate 
      the cardiovascular outcomes of insulin detemir (IDet) versus insulin glargine 
      (IGlar) in T2DM patients after ACS or AIS. METHODS: A retrospective cohort study 
      was conducted between June 1, 2005, and December 31, 2013, utilizing the Taiwan 
      National Health Insurance Research Database. A total of 3,129 ACS or AIS patients 
      were eligible for the analysis. Clinical outcomes were evaluated by comparing 
      1,043 subjects receiving IDet with 2,086 propensity score-matched subjects who 
      received IGlar. The primary composite outcome included cardiovascular (CV) death, 
      nonfatal myocardial infarction (MI) and nonfatal stroke. RESULTS: The primary 
      composite outcome occurred in 322 patients (30.9%) in the IDet group and 604 
      patients (29.0%) in the IGlar group (hazard ratio [HR], 1.12; 95% confidence 
      interval [CI], 0.95 to 1.32) with a mean follow-up of 2.4 years. No significant 
      differences were observed for CV death (HR, 1.09; 95% CI, 0.86 to 1.38), nonfatal 
      MI (HR, 0.88; 95% CI, 0.66 to 1.19), and nonfatal stroke (HR, 1.15; 95% CI, 0.97 
      to 1.35). There were similar risks of all-cause mortality, hospitalization for 
      heart failure and revascularization between the IDet group and the IGlar group (P 
      = .647, .115, and .390 respectively). CONCLUSION: Compared with IGlar, in T2DM 
      patients after ACS or AIS, IDet was not associated with increased risks of CV 
      death, nonfatal MI, or nonfatal stroke. ABBREVIATIONS: ACS = acute coronary 
      syndrome; AIS = acute ischemic stroke; ASCVD = atherosclerotic cardiovascular 
      disease; CI = confidence interval; CV = cardiovascular; DKA = diabetic 
      ketoacidosis; HHF = hospitalization for heart failure; HHS = hyperosmolar 
      hyperglycemic state; HR = hazard ratio; IDet = insulin detemir; IGlar = insulin 
      glargine; MI = myocardial infarction; NHIRD = National Health Insurance Research 
      Database; PCI = percutaneous coronary intervention; PSM = propensity score 
      matching; T2DM = type 2 diabetes mellitus.
CI  - (c) 2020 American Association of Clinical Endocrinologists. Published by Elsevier, 
      Inc. All rights reserved.
FAU - Chen, Tien-Hsing
AU  - Chen TH
AD  - Tien-Hsing Chen and Chih-Ching Wang contributed equally as the first author.; 
      From the Division of Cardiology, Department of Internal Medicine, Keelung Chang 
      Gung Memorial Hospital, Keelung, Taiwan.
FAU - Wang, Chih-Ching
AU  - Wang CC
AD  - Tien-Hsing Chen and Chih-Ching Wang contributed equally as the first author.; the 
      Division of Endocrinology and Metabolism, Department of Internal Medicine, Linkou 
      Chang Gung Memorial Hospital, Taoyuan, Taiwan.
FAU - Liu, Chi-Hung
AU  - Liu CH
AD  - the Stroke Center and Department of Neurology, Linkou Chang Gung Memorial 
      Hospital, Taoyuan, Taiwan.
FAU - Hsiao, Ching-Chung
AU  - Hsiao CC
AD  - the Kidney Research Center and Department of Nephrology, Taipei Chang Gung 
      Memorial Hospital, Taipei, Taiwan.
FAU - Chen, Szu-Tah
AU  - Chen ST
AD  - the Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.
FAU - Liu, Feng-Hsuan
AU  - Liu FH
AD  - the Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.
FAU - Ho, Ming-Yun
AU  - Ho MY
AD  - the Division of Cardiology, Department of Internal Medicine, Linkou Chang Gung 
      Memorial Hospital, Taoyuan, Taiwan.
FAU - Li, Yan-Rong
AU  - Li YR
AD  - the Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan; the College of Medicine, 
      Chang Gung University, Taoyuan, Taiwan.. Electronic address: mr8252@cgmh.org.tw.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Endocr Pract
JT  - Endocrine practice : official journal of the American College of Endocrinology 
      and the American Association of Clinical Endocrinologists
JID - 9607439
RN  - 2ZM8CX04RZ (Insulin Glargine)
RN  - 4FT78T86XV (Insulin Detemir)
SB  - IM
MH  - *Brain Ischemia
MH  - *Cardiovascular Diseases/epidemiology
MH  - Cohort Studies
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy/epidemiology
MH  - Humans
MH  - Insulin Detemir/adverse effects
MH  - Insulin Glargine/adverse effects
MH  - *Percutaneous Coronary Intervention
MH  - Retrospective Studies
MH  - *Stroke/epidemiology/etiology
MH  - Taiwan/epidemiology
MH  - Treatment Outcome
EDAT- 2021/01/21 06:00
MHDA- 2021/01/23 06:00
CRDT- 2021/01/20 17:09
PHST- 2019/11/27 00:00 [received]
PHST- 2020/03/03 00:00 [accepted]
PHST- 2021/01/20 17:09 [entrez]
PHST- 2021/01/21 06:00 [pubmed]
PHST- 2021/01/23 06:00 [medline]
AID - S1530-891X(20)48165-0 [pii]
AID - 10.4158/EP-2019-0552 [doi]
PST - ppublish
SO  - Endocr Pract. 2020 Aug;26(8):818-829. doi: 10.4158/EP-2019-0552.